Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly

Clinical Endocrinology

Volumn 82, Issue 6, 2015, Pages 900-909

  Holecki, Michał ^a   Chudek, Jerzy ^a   Owczarek, Aleksander ^a   Olszanecka Glinianowicz, Magdalena ^a   Bozentowicz Wikarek, Maria ^a   Duława, Jan ^a   Mossakowska, Małgorzata ^b   Zdrojewski, Tomasz ^c   Skalska, Anna ^d   Więcek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CALCIFEDIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; INSULIN; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS; BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR; IL6 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ANTHROPOMETRY; ARTICLE; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CREATININE BLOOD LEVEL; FEMALE; GERIATRIC ASSESSMENT; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; NURSE; NUTRITIONAL STATUS; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; VERY ELDERLY; VITAMIN BLOOD LEVEL; BLOOD; ENERGY METABOLISM; HEALTH SURVEY; METABOLISM; PHYSIOLOGY; POLAND; REGRESSION ANALYSIS;

AGED; CALCIFEDIOL; ENERGY METABOLISM; FEMALE; FIBROBLAST GROWTH FACTORS; GERIATRIC ASSESSMENT; HEALTH SURVEYS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; POLAND; REGRESSION ANALYSIS;

EID: 84929707931     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12759     Document Type: Article

References (37)

1. Yamashita, T., Yoshioka, M., &, Itoh, N., (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and Biophysical Research Communications, 277, 494-498.
2. Shimada, T., Hasegawa, H., Yamazaki, Y., et al,. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research, 19, 429-435.
3. Holecki, M., Chudek, J., Więcek, A., et al,. (2011) The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. International Journal of Endocrinology, 2011, 707126.
4. Fernández-Real, J.M., Puig, J., Serrano, M., et al,. (2013) Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS ONE, 8, e58961.
5. Mirza, M.A., Alsiö, J., Hammarstedt, A., et al,. (2011) Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 219-227.
6. Wojcik, M., Dolezal-Oltarzewska, K., Janus, D., et al,. (2012) FGF-23 contributes to insulin sensitivity in obese adolescents-preliminary results. Clinical Endocrinology (Oxford), 77, 537-540.
7. Kocełak, P., Olszanecka-Glinianowicz, M., &, Chudek, J., (2012) Fibroblast growth factor 23-structure, function and role in kidney diseases. Advances in Clinical and Experimental Medicine, 21, 391-401.
8. Błędowski, P., Mossakowska, M., Chudek, J., et al,. (2011) Medical, psychological, social, and economic aspects of aging in Poland (PolSenior): research assumptions and objectives. Experimental Gerontology, 46, 1003-1009.
9. Levey, A.S., Stevens, L.A., Schmid, C.H., et al,. (2009) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150, 604-612.
10. World Health Organization. (2000) Technical Report Series 894: Obesity: Preventing and Managing the Global Epidemic. World Health Organization, Geneva.
11. Alberti, K.G., Zimmet, P., &, Shaw, J., (2006) Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine, 23, 469-480.
12. American Diabetes Association (2013) Standards of medical care in diabetes-2013. Diabetes Care, 36 (Suppl 1), S11-S66.
13. Nadrowski, P., Chudek, J., Grodzicki, T., et al,. (2013) Plasma level of N-terminal pro brain natriuretic peptide (NT-proBNP) in elderly population in Poland-The PolSenior Study. Experimental Gerontology, 48, 852-857.
14. Antoniucci, D., Yamashita, T., &, Portale, A., (2011) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. Journal of Clinical Endocrinology and Metabolism, 91, 3144-3149.
15. Gutierrez, O., Wolf, M., &, Taylor, E., (2011) Fibroblast growth factor 23, cardiovascular disease risk factor, and phosphorus intake in the health professionals follow-up study. Clinical Journal of the American Society of Nephrology: CJASN, 6, 2871-2878.
16. Di Iorio, B., Di Micco, L., Torraca, S., et al,. (2012) Acute effect of very-low-protein diet on FGF23 levels: a randomized study. Clinical Journal of the American Society of Nephrology: CJASN, 7, 581-587.
17. Rosen, C.J., (2011) Vitamin D insufficiency. New England Journal of Medicine, 364, 248-254.
18. Winther, K., Nybo, M., Vind, B., et al,. (2012) Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients. Scandinavian Journal of Clinical and Laboratory Investigation, 72, 108-113.
19. Isakova, T., Wahl, P., Vargas, G.S., et al,. (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International, 79, 1370-1378.
20. Yilmaz, M.I., Sonmez, A., Saglam, M., et al,. (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney International, 78, 679-685.
21. Gutiérrez, O.M., Januzzi, J.L., Isakova, T., et al,. (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 119, 2545-2552.
22. Gutiérrez, O.M., Mannstadt, M., Isakova, T., et al,. (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New England Journal of Medicine, 359, 584-592.
23. Isakova, T., Xie, H., Yang, W., et al,. (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 305, 2432-2439.
24. Poelzl, G., Trenkler, C., Kliebhan, J., et al,. (2014) FGF23 is associated with disease severity and prognosis inchronic heart failure. European Journal of Clinical Investigation, 44, 1150-1158.
25. Munoz Mendoza, J., Isakova, T., Ricardo, A.C., et al,. (2012) Fibroblast growth factor 23 and inflammation in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 7, 1155-1162.
26. Nasrallah, M.M., El-Shehaby, A.R., Osman, N.A., et al,. (2013) The association between fibroblast growth factor-23 and vascular calcification is mitigated by inflammation markers. Nephron Extra, 3, 106-112.
27. Chudek, J., Wieczorowska-Tobis, K., Zejda, J., et al,. (2014) The prevalence of chronic kidney disease and its relation to socioeconomic conditions in the elderly Polish population: results from the national population-based study PolSenior. Nephrology, Dialysis, Transplantation, 29, 1073-1082.
28. Castell, J., Gómez-Lechón, M., David, M., et al,. (1989) Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters, 242, 237-239.
29. Axelsson, J., Rashid Qureshi, A., Suliman, M., et al,. (2004) Truncal fat mass as a contributor to inflammation in end-stage renal disease. American Journal of Clinical Nutrition, 80, 1222-1229.
30. Wisse, B.E., (2004) The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. Journal of the American Society of Nephrology, 15, 2792-2800.
31. Dai, B., David, V., Martin, A., et al,. (2012) A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE, 9, e44161.
32. Olszanecka-Glinianowicz, M., Chudek, J., Kocełak, P., et al,. (2011) Body fat changes and activity of tumor necrosis factor α system-a 5-year follow-up study. Metabolism, 60, 531-536.
33. Grethen, E., Hill, K.M., Jones, R., et al,. (2012) Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. Journal of Clinical Endocrinology and Metabolism, 97, 1655-1662.
34. Tsuji, K., Maeda, T., Kawane, T., et al,. (2010) Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. Journal of Bone and Mineral Research, 25, 1711-1723.
35. Saini, R.K., Kaneko, I., Jurutka, P.W., et al,. (2013) 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcified Tissue International, 92, 339-353.
36. Nilsson, J., (2005) CRP-marker or marker of cardiovascular disease? Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1527-1528.
37. Jin, X., Beguerie, J., Blizzard, L., et al,. (2015) Circulating C reactive protein in osteoarthritis: a systemic review and meta-analysis. Annals of the Rheumatic Diseases 74, 703-710.